China's Innovative Drug Out-Licensing Hits $110 Billion in 1H 2026, Sets Record

According to China's State Drug Administration and state broadcaster CCTV, innovative drug out-licensing deals in China reached approximately $110 billion in the first half of 2026, representing 80% of the full-year 2025 total and marking a new historical high.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments